By / September 25, 2020

Medical cannabis could mitigate Parkinson’s non-motor symptoms

A group of Austrian scientists have successfully completed research which could prove that medical cannabis can mitigate non-motor Parkinson’s symptoms, such as perceptual disorders and other autonomic nervous system dysfunctions. This could change the way doctors treat this disease and become a powerful ally against it.

“This is the first time a randomized controlled study was done to examine the efficacy and safety of medical cannabis in the treatment of non-motor symptoms in patients with Parkinson’s disease,” the Innsbruck University Neurology Clinic reported in a statement on Thursday. 

The result of the research has been published in the specialized journal Annals of Neurology and serves as potential proof that medical cannabis is a viable way to treat many diseases, and has the potential to change the medical landscape around the world.

If you want to know more about cannabis, how medical cannabis can serve as a powerful ally in the fight against multiple diseases, how Parkinson’s symptoms could be mitigated by using cannabis, and to find out the latest cannabis news, download the mobile application.

Cannabis could be the key to treat non-motor Parkinson’s symptoms

According to neurologist Klaus Seppi, one of the study authors, normally Parkinson’s is associated with tremors or muscle stiffness, but the truth is that “many patients suffer non-motor symptoms: they have depression, anxiety, problems sleeping. They are very common” he explained, making an emphasis that these can be treated with cannabis, according to the data gathered in the latest research. 

“We have ample evidence that motor symptoms are treatable, but for non-motor symptoms there are hardly any treatments,” warns the Austrian researcher. He also reminds us that these can appear years before mobility problems develop, affecting the quality of life of the patients.

Cannabis research focused on ‘Nabilone’ as the main target

The medical study was carried out using a synthetic cannabinoid named ‘Nabilone’ , which has pharmacological properties similar to the common psychoactive component of cannabis.

“We decided to use ‘Nabilone’ because the company that produces it also supplies the placebo, but we could also have used other compounds with similar characteristics”, clarifies the scientist, who also mention that it was his own Parkinson’s patients who inspired the study, as they asked him to prescribe them medical cannabis.

“95% of neurologists from the Center of Excellence of the National Parkinson Research Foundation who participated in a survey on cannabis use had patients who asked for cannabis prescription”, this can be read in the statement from the University Clinic of Innsbruck Neurology

The researchers are hopeful that their work can serve as the basis for future cannabis studies, and that the study will help endorse this medicinal plant as a viable treatment for non-motor Parkinson’s symptoms. 

“The problem is that it is very difficult to motivate pharmaceutical companies to carry out a trial”, since ‘Nabilone’ is very easy to produce and there is “a lot of supply” , warns Klaus Seppi, who maintains contacts to prepare a further trial , since the one that has been published is “completely academic, and to carry out a phase III study with only the University’s means would be impossible.”


(Featured image by Matheus Ferrero via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Marca, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.